QLIFE®  GINGKO BILOBA 24-% Extract
PRODUCT INFORMATION AND LINK PAGE

DISCLAIMER: This product is not intended to diagnose, treat, cure or prevent any disease.
BATORY A.M., Inc. makes no claims whatsoever as to any benefits of this product beyond its value as a dietary supplement.

PRODUCT INFORMATION:
Name: QLIFE® GINGKO BILOBA Dietary Supplement
Each capsule contains: 60 mg Gingko Biloba standardized extract: 24% gingko flavonglycosides and 6% terpene lactones.
Directions: For mature adults to take by mouth one capsule, 3 times a day at mealtime, with a large glass of water. Allow 12 weeks of the use before determining its efficacy.
Warning: Mild gastrointestinal upset occurred in <1% of patients in clinical studies. Individuals with poor blood flow to the brain (i.e., cerebrovascular insufficiency) may experience a mild, transient headache for the first one or two days of use. There are no known interactions with commonly prescribed drugs. The current German Commission E Monograph lists no contraindications to the use of gingko during pregnancy or lactation.


SELECTED THIRD-PARTY LITERATURE FOLLOWS
Claims contained in the selected pieces of the third party literature appearing below have not been assessed by the Food and Drug Administration.


                    Gingko Biloba Can Stabilize and Even Improve Dementia
                         Changes substantial enough to be noticed by caregivers
                         WASHINGTON, D.C.—An extract of Ginkgo biloba can stabilize and,
                         in some cases, improve the cognitive function and the social behavior of
                         demented patients for six months to one year, according to an article in
                         the October 22 issue of The Journal of the American Medical
                         Association (JAMA), a theme issue on aging.
                         Pierre L. LeBars, M.D., Ph.D., from the New York Institute for
                         Medical Research, Tarrytown, N.Y., and colleagues reported beneficial
                         effects of EGb 761, a particular extract of Ginkgo biloba, compared to
                         placebo in a study of 309 demented patients with mild to moderately
                         severe cognitive impairment caused by Alzheimer disease, vascular
                         dementia or a combination of the two.
                         Dr. LeBars presented the findings of the first empirical clinical trial of
                         the Gingko biloba extract conducted in the U.S. today at the AMA's
                         16th Annual Science Reporters Conference. The research was a one
                         year, double blind, placebo-controlled, parallel-group, multicenter study.
                         The authors conclude: "EGb appears to stabilize and, in an additional 20
                         percent of cases (vs. placebo), improve the patient's functioning for
                         periods of six months to one year. Regarding its safety, adverse events
                         associated with EGb were no different from those associated with
                         placebo."
                         The researchers found that 27 percent of patients treated 26 weeks or
                         more with EGb achieved at least a four point improvement on the 70
                         point Alzheimer Disease Assessment Scale-Cognitive subscale
                         (ADAS-Cog), compared with 14 percent taking placebo; on the
                         Geriatric Evaluation by Relative's Rating Instrument (GERRI), the daily
                         living and the social behavior of 37 percent were considered improved
                         with EGb, compared to 23 percent taking placebo.
                         The authors write: "On the ADAS-Cog, 50 percent of the EGb patients
                         showed an improvement by at least two points compared with 29
                         percent of the placebo group; this approximately two-fold difference
                         was still observed when the threshold to detect an improvement in
                         cognition was set at four ADAS-Cog points. On GERRI, 37 percent of
                         the EGb group was considered improved while only 19 percent were
                         considered worse; the placebo group demonstrated the opposite trend
                         with 40 percent worsening and 23 percent improving."
                         The extract of Ginkgo biloba, EGb 761, is a popular plant extract used in
                         Europe that has recently been approved in Germany for the treatment of
                         dementia. How EGb acts on the central nervous system is not
                         completely understood. It contains compounds that scavenge free
                         radicals some believe to be the mediators of the excessive lipid
                         peroxidation and cell damages observed in Alzheimer disease.
                         The study results demonstrated that EGb had a measurable effect on
                         cognitive impairment and daily living and social behavior in patients with
                         dementia. Although the treatment effect could not be detected by the
                         clinician's global impression of change, it was demonstrated through
                         objective tests of cognitive performance and was identified by the
                         caregiver.
                         The researchers state: "Compared with the placebo group, the EGb
                         group included twice as many patients whose cognitive performance
                         improved and half as many whose social functioning worsened. In
                         clinical terms, improvement on the ADAS-Cog of four points may be
                         equivalent to a six-month delay in the progression of the disease."
                         (JAMA. 1997;278:1327-1332)

From: The Honest Herbal Varro E. Tyler, PhD, Pharmaceutical Products Press, third ed, 1993.
The ginkgo tree has survived in China for almost 200 million years; the fruits and seeds have been used there since 2800 B.C. Only recently, however, has the West gotten in touch with ginkgo biloba's helpful properties. In 1988, doctors in Germany (where it's sold as an over-the-counter drug) wrote more prescriptions for it than other prescription drugs. In the U.S., it's currently marketed only as a health food supplement.
Gingko biloba is most effective as a concentrated extract, found in either liquid or tablet form. It has beneficial effects on the
circulatory system, particularly among the elderly. Studies have shown it can help in treatment of their short-term memory loss,
headache, tinnitus (ringing in the ears) and depression by improving blood flow in the arteries and capillaries.
This remnant of the dinosaur age can help our own aging population feel a little less "prehistoric."

From Smart Drugs and Nutrients:
GINKGO BILOBA: A Nootropic Herb?
Extracts from the leaves of the ginkgo biloba tree have been used by Chinese medicine for thousands of years. European physicians write over 1.2 million prescriptions per month for it. Ginkgo biloba is used to improve cerebral circulation, mental alertness, and overall brain functioning.
More than 34 human studies on ginkgo have been published since 1975, showing that ginkgo works by increasing blood flow
throughout the body and brain. Ginkgo increases the productions of adenosine triphosphate (ATP, the universal energy molecule). It also improves the brain's ability to metabolize glucose, prevents platelet aggregation inside arterial walls by keeping them flexible, improves the transmission of nerve signals, and acts as a powerful antioxidant.
Ginkgo biloba leaf is effective for people with symptoms of reduced blood flow to the brain and extremities. It has been shown to be helpful with many of the complaints of the elderly such as: memory loss, slow thinking and reasoning, depression, dizziness, ringing in the ears, headaches, and senile macular degeneration (a major cause of blindness).
One study even shows significant improvement in people who have both Parkinson's and Alzheimer's disease. In this study 25
people with Parkinson's disease and signs of Alzheimer's disease were given ginkgo extract daily for one year. They were tested with standard tests, clinical evaluations, and a new computerized EEG. The scores improved significantly.

 Other nice links to information on Gingko Biloba:
Wisdom from the Oldest Tree
Ginkgo Updated

 Talk to Us | PLACE ORDER
melatoninArticles | melatoninBackground | melatoninResearch
 
 | DHEA | St. John's Wort
 | TESTIMONIALS |